RxDoctor Payments Data

Jeffrey Salin, DO

Orthopaedic Surgery · Overland Park, KSNPI 1407800725

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $35,750 of the $40,885 with a category attached, or 87.4%. Zimmer Biomet accounts for 98.9% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $26,457 and has fallen 99.9% since, to $20 in 2025.

$40,885in general payments, 2019–2025

Across 100 payments — averaging $408.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Zimmer Biomet$40K
  • Ferring Pharmaceuticals Inc.$146
  • Heron Therapeutics, Inc.$89
  • Amgen$51
  • Pacira Therapeutics, Inc.$45
  • Stryker$30
  • plus $105 from 6 others

What the payments were for

  • Consulting fees$35,75087%
  • Travel & lodging$3,91710%
  • Food & beverage$1,2183%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,885 in reported general payments places this provider in the 85th percentile of 197 orthopaedic surgery providers in Kansas.

See all orthopaedic surgery providers in Kansas

Medicare billing

Part B allowed, 2024
$486,685
Medicare patients
793
Services billed
3,023

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban78$40,184
Celecoxib349$7,420
Mupirocin361$2,612
Cephalexin77$742
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen66$699
Pregabalin90$693
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst50$573
Gabapentin442$492
Amoxicillin344$410
Oxycodone Hcl63$389
Ondansetron OdtOndansetron38$309
Meloxicam154$283
Clindamycin Hcl62$133
Cyclobenzaprine Hcl13$58
Tramadol Hcl27$58

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$29$40,18478 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 197 orthopaedic surgery providers in Kansas.

Other orthopaedic surgery in Overland Park

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →